OCS Stock Summary and Trading Ideas (Oculis Holding Ag - | NASDAQ:OCS)

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.

As of November 10, 2026, OCS stock price declined to $7.59 with 250,861 million shares trading.

OCS has a beta of 2.79, meaning it tends to be more sensitive to market movements. OCS has a correlation of 0.14 to the broad based SPY ETF.

OCS has a market cap of $438.75 million. This is considered a Small Cap stock.

Last quarter Oculis Holding Ag - reported $8,619 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-281,381 and exceeded earnings estimates by $.12.

In the last 3 years, OCS traded as high as $34.48 and as low as $6.78.

The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, GWX, ONEQ, BBC.

OCS has underperformed the market in the last year with a price return of -60.9% while the SPY ETF gained +11.2%. OCS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.5% and -3.1%, respectively, while the SPY returned -2.7% and -2.6%, respectively.

OCS support price is $7.39 and resistance is $8.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.